{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:28:34Z","timestamp":1791440914281,"version":"4.3.3"},"reference-count":34,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":2878,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To determine time to treatment intensification in people with type 2 diabetes treated with one, two, or three oral antidiabetes drugs (OADs) and associated levels of glycemic control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This was a retrospective cohort study based on 81,573 people with type 2 diabetes in the U.K. Clinical Practice Research Datalink between January 2004 and December 2006, with follow-up until April 2011.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>In people with HbA1c \u22657.0, \u22657.5, or \u22658.0% (\u226553, \u226558, or \u226564 mmol\/mol), median time from above HbA1c cutoff to intensification with an additional OAD was 2.9, 1.9, or 1.6 years, respectively, for those taking one OAD and &amp;gt;7.2, &amp;gt;7.2, and &amp;gt;6.9 years for those taking two OADs. Median time to intensification with insulin was &amp;gt;7.1, &amp;gt;6.1, or 6.0 years for those taking one, two, or three OADs. Mean HbA1c at intensification with an OAD or insulin for people taking one, two, or three OADs was 8.7, 9.1, and 9.7%. In patients taking one, two, or three OADs, median time from treatment initiation to intensification with an OAD or insulin exceeded the maximum follow-up time of 7.2 years. The probability of patients with poor glycemic control taking one, two, or three OADs, intensifying at end of follow-up with an OAD, was 21.1\u201343.6% and with insulin 5.1\u201312.0%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>There are delays in treatment intensification in people with type 2 diabetes despite suboptimal glycemic control. A substantial proportion of people remain in poor glycemic control for several years before intensification with OADs and insulin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc13-0331","type":"journal-article","created":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T04:15:05Z","timestamp":1374552905000},"page":"3411-3417","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":559,"title":["Clinical Inertia in People With Type 2 Diabetes"],"prefix":"10.2337","volume":"36","author":[{"given":"Kamlesh","family":"Khunti","sequence":"first","affiliation":[{"name":"Diabetes Research Centre, College of Medicine, Biological Sciences & Psychology, University of Leicester, Leicester Diabetes Centre, Leicester General Hospital, Leicester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wolden","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Larsen","family":"Thorsted","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andersen","sequence":"additional","affiliation":[{"name":"StatGroup ApS, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, College of Medicine, Biological Sciences & Psychology, University of Leicester, Leicester Diabetes Centre, Leicester General Hospital, Leicester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,10,15]]},"reference":[{"key":"2022031302063392900_B1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"2022031302063392900_B2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"2022031302063392900_B3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031302063392900_B4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc12-s011","article-title":"Standards of medical care in diabetes\u20142012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031302063392900_B5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"2022031302063392900_B6"},{"key":"2022031302063392900_B7","unstructured":"National Institute for Health and Care Excellence. NICE clinical guideline 87. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes [article online], 2009. Available from www.nice.org.uk\/cg87shortguideline. Accessed 10 October 2012"},{"key":"2022031302063392900_B8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1742-1241.2008.01917.x","article-title":"The IMPROVE study\u2014a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts","volume":"62","author":"Valensi","year":"2008","journal-title":"Int J Clin Pract"},{"key":"2022031302063392900_B9","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/j.1742-1241.2008.01939.x","article-title":"Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study","volume":"62","author":"Sreenan","year":"2008","journal-title":"Int J Clin Pract"},{"key":"2022031302063392900_B10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.diabres.2011.10.021","article-title":"An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study","volume":"94","author":"Home","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031302063392900_B11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2337\/diacare.27.7.1535","article-title":"The burden of treatment failure in type 2 diabetes","volume":"27","author":"Brown","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031302063392900_B12","first-page":"455","article-title":"Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study","volume":"57","author":"Calvert","year":"2007","journal-title":"Br J Gen Pract"},{"key":"2022031302063392900_B13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/0145721705279050","article-title":"Clinical inertia contributes to poor diabetes control in a primary care setting","volume":"31","author":"Ziemer","year":"2005","journal-title":"Diabetes Educ"},{"key":"2022031302063392900_B14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2337\/diacare.28.3.600","article-title":"Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?","volume":"28","author":"Shah","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031302063392900_B15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2125.1998.00701.x","article-title":"Use of the UK General Practice Research Database for pharmacoepidemiology","volume":"45","author":"Garc\u00eda Rodr\u00edguez","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"2022031302063392900_B16","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3399\/bjgp10X483562","article-title":"Validity of diagnostic coding within the General Practice Research Database: a systematic review","volume":"60","author":"Khan","year":"2010","journal-title":"Br J Gen Pract"},{"key":"2022031302063392900_B17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1464-5491.2006.01838.x","article-title":"Mortality in people with type 2 diabetes in the UK","volume":"23","author":"Mulnier","year":"2006","journal-title":"Diabet Med"},{"key":"2022031302063392900_B18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/sj.bjc.6602102","article-title":"A note on competing risks in survival data analysis","volume":"91","author":"Satagopan","year":"2004","journal-title":"Br J Cancer"},{"key":"2022031302063392900_B19","doi-asserted-by":"crossref","DOI":"10.1002\/9780470870709","volume-title":"Competing Risks: A Practical Perspective","author":"Pintilie","year":"2006"},{"key":"2022031302063392900_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/175709311X13141797023422","article-title":"SAS code for the estimation and between-group comparison of cumulative incidence functions in competing risks survival analysis","volume":"4","author":"Bond","year":"2011","journal-title":"Pharmaceutical Programming"},{"key":"2022031302063392900_B21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11606-007-0139-y","article-title":"Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy","volume":"22","author":"Nichols","year":"2007","journal-title":"J Gen Intern Med"},{"key":"2022031302063392900_B22","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1464-5491.2007.02279.x","article-title":"Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK","volume":"24","author":"Rubino","year":"2007","journal-title":"Diabet Med"},{"key":"2022031302063392900_B23","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.2337\/dc09-S314","article-title":"Changing the treatment paradigm for type 2 diabetes","volume":"32","author":"Del Prato","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031302063392900_B24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2337\/dc06-2170","article-title":"Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management","volume":"30","author":"Grant","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031302063392900_B25","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.2337\/dc11-s235","article-title":"Multidrug treatment of type 2 diabetes: a challenge for compliance","volume":"34","author":"Miccoli","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031302063392900_B26","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","article-title":"Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study","volume":"28","author":"Peyrot","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031302063392900_B27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1464-5491.1991.tb01699.x","article-title":"Initiation of insulin treatment after 70 years of age: patient status 2 years later","volume":"8","author":"Elgrably","year":"1991","journal-title":"Diabet Med"},{"key":"2022031302063392900_B28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/qjmed\/93.6.369","article-title":"Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude","volume":"93","author":"Wallace","year":"2000","journal-title":"QJM"},{"key":"2022031302063392900_B29","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031302063392900_B30","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031302063392900_B31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1210\/jc.2008-1824","article-title":"Clinical review 2: the \u201cmetabolic memory\u201d: is more than just tight glucose control necessary to prevent diabetic complications?","volume":"94","author":"Ceriello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031302063392900_B32","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"2022031302063392900_B33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.pcd.2010.07.003","article-title":"Clinical inertia in management of T2DM","volume":"4","author":"Zafar","year":"2010","journal-title":"Prim Care Diabetes"},{"key":"2022031302063392900_B34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1592\/phco.24.4.324.33173","article-title":"Failure of computerized treatment suggestions to improve health outcomes of outpatients with uncomplicated hypertension: results of a randomized controlled trial","volume":"24","author":"Murray","year":"2004","journal-title":"Pharmacotherapy"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/11\/3411\/615569\/3411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/11\/3411\/615569\/3411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T06:14:33Z","timestamp":1647152073000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/11\/3411\/38071\/Clinical-Inertia-in-People-With-Type-2-DiabetesA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,15]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,10,15]]},"published-print":{"date-parts":[[2013,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc13-0331","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,15]]}}}